SUMMARY:
Focal Laser Ablation and external beam radiation are both methods of treating low- to intermediate-risk prostate cancer. Since their mechanisms of destroying cancer cells differ significantly, the two treatments have distinct side effect profiles and ways of evaluating recurrence. The key difference is the immediate effectiveness of Focal Laser Ablation with higher post-treatment quality of life.
How do Focal Laser Ablation and external beam radiation differ for killing cancer?
Both Focal Laser Ablation and radiation are non-surgical treatments to control localized prostate cancer. However, these two methods differ significantly based on the way they destroy cancer cells.
Focal Laser Ablation targets and destroys a specific tumor while avoiding damage to surrounding healthy structures. All cells—both normal and cancerous—are immediately destroyed by laser heat within the treatment zone. Laser temperature is universal to treat low- to intermediate-risk localized tumors.
Radiation therapy, on the other hand, targets the entire gland. Unlike Focal Laser Ablation, however, the effect of applying radiation is not immediate. Rather, as radiation damages cancer DNA, cells die off over several months. While cancer cell DNA is more vulnerable to radiation, exposure to radiation scatter may also damage healthy cell DNA. Radiation dose may vary to treat low-to-high risk localized cancer.
| Focal Laser Ablation | External Beam Radiation |
|
|
How do side effects of Focal Laser Ablation and radiation compare?
Focal Laser Ablation and radiation therapy have different short-term and long-term side effect profiles. Since radiation can gradually damage DNA in healthy as well as cancer tissues, organ damage may occur. Ablation side effects, if they occur, improve quickly, while radiation side effects may worsen over time.
Possible side effects reported in published studies
| Focal Laser Ablation | External Beam Radiation | |
| Less than 2 weeks |
|
|
| Short term |
|
Most resolve after treatment is discontinued |
| Longer term |
|
|
What are the cancer recurrence rates after Focal Laser Ablation and beam radiation?
Currently, there are no side-by-side comparison studies that evaluate cancer control between Focal Laser Ablation and radiation. Since most Focal Laser Ablation studies are single arm studies with follow-up periods ranging from 12 months to 10 years, it is difficult to compare cancer control.
One problem is different definitions of recurrence. Focal Laser Ablation recurrence may be reported as a need for retreatment, whereas radiation recurrence may be reported as biochemical failure (a PSA rise > 0.2 ng/mL, or a rising PSA).
Comparisons are also problematic because studies after Focal Laser Ablation are of shorter duration (up to 10 years) whereas long term rates are reported for beam radiation (15-30+ years).
Reported recurrence rates across studies
| 5-year Focal Laser Ablation (need retreatment) | 10-year Beam Radiation (biochemical failure) |
|
|
How does quality of life after treatment differ between Focal Laser Ablation and beam radiation?
Post-treatment quality of life is generally better during and after Focal Laser Ablation than beam radiation. Although the same diagnostic evaluation applies to either method, and both methods are done as outpatient treatments, they differ along key lines.
- 1 day for Focal Laser Ablation vs. several weeks for radiation
- Rapid return to normal activity vs. daily appointments and fatigue for radiation
- Side effects of Focal Laser Ablation resolve within days to 2 weeks vs. gradually increasing radiation side effects through the treatment period and possibly beyond
- Minimal risk of urinary side effects for Focal Laser Ablation vs. higher urinary irritation profile for radiation
- Minimal risk of sexual side effects for Focal Laser Ablation vs. later onset sexual side effects for radiation
- Treatment effect able to be MRI-monitored after Focal Laser Ablation vs. invisible DNA damage after radiation unable to be monitored
- Immediate confidence that cancer is destroyed after Focal Laser Ablation vs. anxiety while waiting for many months to be sure PSA is not rising
- No known risk for late onset secondary bladder or bowel cancer with Focal Laser Ablation vs. secondary cancer risk due to radiation exposure for beam radiation
Frequently asked questions
Q: Who is a candidate for Focal Laser Ablation?
A: In general, candidates are patients with a low-to-intermediate risk index lesion (main tumor) that is visible on MRI. The tumor and a surrounding margin of safety are of a size to be encompassed by the chosen ablation method. Urinary or sexual structures are not within close contact of the zone of ablation. Patients are those seeking an alternative to whole gland treatment, or who do not wish to go on Active Surveillance. They are willing to comply with scheduled follow-up monitoring. In fact, it is estimated that roughly a third of men diagnosed with localized prostate cancer would qualify for Focal Laser Ablation.
Q: My doctor says Active Surveillance is now the preferred treatment for low-risk prostate cancer. Why?
A: Over a decade ago, experts recognized that whole-gland treatment, with its side effect risks, is overtreatment because it harms quality of life for patients whose cancer was not life-threatening. Studies showed that holding off on treatment a) had no urinary or sexual consequences and b) men on Active Surveillance had almost the same life expectancy as men who had surgery or radiation. So, there were two choices with no middle ground: treat the whole gland, or don’t treat it at all.
Between then and now, MRI and targeted biopsy made it possible to identify men with unifocal disease who could have their tumor destroyed with minimal risk of side effects. Thus, focal therapy emerged as a balance between the two extremes. While a patient’s clinical factors point him toward Active Surveillance, in fact many patients don’t like the idea of living with cancer growing in them, or they find monitoring too heavy of a burden, or they don’t want to chance missing a treatment window. In other words, your paperwork might say you should go on Active Surveillance, but you want to get rid of the cancer without harming your lifestyle. In such cases, it’s worth being evaluated to find out if you’re a candidate for focal therapy.
Content reviewed by Dr. Dan Sperling, M.D., DABR — updated September 2026
NOTE: This content is solely for purposes of information and does not substitute for diagnostic or medical advice. Talk to your doctor if you are experiencing pelvic pain, or have any other health concerns or questions of a personal medical nature.
About Dr. Dan Sperling
Dan Sperling, MD, DABR, is a board certified radiologist who is globally recognized as a leader in multiparametric MRI for the detection and diagnosis of a range of disease conditions. As Medical Director of the Sperling Prostate Center, Sperling Medical Group and Sperling Neurosurgery Associates, he and his team are on the leading edge of significant change in medical practice. He is the co-author of the new patient book Redefining Prostate Cancer, and is a contributing author on over 25 published studies. For more information, contact the Sperling Prostate Center.
